SG11201407619SA - Schmallenberg virus (sbv) vaccine, methods of production, and uses thereof - Google Patents

Schmallenberg virus (sbv) vaccine, methods of production, and uses thereof

Info

Publication number
SG11201407619SA
SG11201407619SA SG11201407619SA SG11201407619SA SG11201407619SA SG 11201407619S A SG11201407619S A SG 11201407619SA SG 11201407619S A SG11201407619S A SG 11201407619SA SG 11201407619S A SG11201407619S A SG 11201407619SA SG 11201407619S A SG11201407619S A SG 11201407619SA
Authority
SG
Singapore
Prior art keywords
ingelheim
international
boehringer
rhein
gmbh
Prior art date
Application number
SG11201407619SA
Inventor
Veljko Nikolin
Konrad Stadler
Axel Lischewski
Alexander Brix
Jeffrey P Knittel
Katharina Hedwig Toepfer
Original Assignee
Boehringer Ingelheim Vetmed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmed filed Critical Boehringer Ingelheim Vetmed
Publication of SG11201407619SA publication Critical patent/SG11201407619SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/12011—Bunyaviridae
    • C12N2760/12021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/12011—Bunyaviridae
    • C12N2760/12022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/12011—Bunyaviridae
    • C12N2760/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/12011—Bunyaviridae
    • C12N2760/12061—Methods of inactivation or attenuation
    • C12N2760/12063—Methods of inactivation or attenuation by chemical treatment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 5 December 2013 (05.12.2013) WIPOIPCT (10) International Publication Number WO 2013/181270 A1 (51) International Patent Classification: C07K14/175 (2006.01) A61K39/12 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/US2013/043146 29 May 2013 (29.05.2013) English English (30) Priority Data: 12170631.1 13157875.9 1 June 2012 (01.06.2012) EP 5 March 2013 (05.03.2013) EP (71) Applicant (for all designated States except US): BOEHRINGER INGELHEIM VETMEDICA GMBH [DE/DE]; Binger Strasse 173, 55216 Ingelheim am Rhein (DE). (72) Inventors; and (71) Applicants (for US only): NIKOLIN, Veljko [RS/DE]; Boehringer Ingelheim GmbH, Corporate Patents, Binger Strasse 173, 55216 Ingelheim am Rhein (DE). STADLER, Konrad [AT/DE]; Boehringer Ingelheim GmbH, Corpor­ ate Patents, Binger Strasse 173, 55216 Ingelheim am Rhein (DE). LISCHEWSKI, Axel [DE/DE]; Boehringer Ingle- him GmbH, Corporate Patents, Binger Strasse 173, 55216 Ingelheim am Rhein (DE). BRIX, Alexander [DE/US]; c/o VP, IP, Legal, Boehringer Ingelheim USA Corp., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT 06877- 0368 (US). KNITTEL, Jeffrey P. [US/US]; c/o VP, IP, Legal, Boehringer Ingelheim USA Corp., 900 Ridgebury Rd., P.O. Box 368, Ridgefield, Connecticut 06877-0368 (US). TOEPFER, Katharina Hedwig [DE/DE]; Boehringer Ingelheim GmbH, Corporate Patents, Binger Strasse 173, 55216 Ingelheim am Rhein (DE). (74) Agents: MORRIS, Michael P. et al.; Boehringer Ingel­ heim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT 06877-0368 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) © l> CJ i-H 00 i-H o CJ (54) Title: SCHMALLENBERG VIRUS (SBV) VACCINE, METHODS OF PRODUCTION, AND USES THEREOF (57) Abstract: The present invention relates to the field of vaccines and medicaments for the prophylaxis and treatment of infectious diseases in ruminants. In particular, relates it to inactivated Schmallenberg virus (SBV) useful as vaccine or medicament for prevent­ ing or treating viremia, the transmission and clinical symptoms, in particular malformations in newborn ruminants such as cattle, sheep and goats, induced by SBV.
SG11201407619SA 2012-06-01 2013-05-29 Schmallenberg virus (sbv) vaccine, methods of production, and uses thereof SG11201407619SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12170631 2012-06-01
EP13157875 2013-03-05
PCT/US2013/043146 WO2013181270A1 (en) 2012-06-01 2013-05-29 Schmallenberg virus (sbv) vaccine, methods of production, and uses thereof

Publications (1)

Publication Number Publication Date
SG11201407619SA true SG11201407619SA (en) 2014-12-30

Family

ID=48607368

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201407619SA SG11201407619SA (en) 2012-06-01 2013-05-29 Schmallenberg virus (sbv) vaccine, methods of production, and uses thereof

Country Status (17)

Country Link
US (2) US9370562B2 (en)
EP (1) EP2855513B1 (en)
JP (1) JP6250649B2 (en)
CN (1) CN104350066B (en)
AR (1) AR091240A1 (en)
AU (1) AU2013267453C1 (en)
BR (1) BR112014029515A2 (en)
CA (1) CA2872961A1 (en)
DK (1) DK2855513T3 (en)
EA (1) EA034543B1 (en)
ES (1) ES2617351T3 (en)
IN (1) IN2014DN08927A (en)
MX (1) MX363044B (en)
PL (1) PL2855513T3 (en)
SG (1) SG11201407619SA (en)
UY (1) UY34840A (en)
WO (1) WO2013181270A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2855513T3 (en) 2012-06-01 2017-03-13 Boehringer Ingelheim Vetmedica Gmbh SCHMALLENBERGVIRUS (SBV) VACCINE, PROCEDURES FOR MANUFACTURING AND USING THEREOF
WO2013178711A1 (en) 2012-06-01 2013-12-05 Boehringer Ingelheim Vetmedica Gmbh Genomic sequences of schmallenberg virus and uses thereof
EP2968514A1 (en) * 2013-03-12 2016-01-20 Merial, Inc. Reverse genetics schmallenberg virus vaccine compositions, and methods of use thereof
CN104232587B (en) * 2014-09-02 2016-08-17 中国检验检疫科学研究院 Cell line and the application thereof of Maron shellfish lattice virus nucleocapsid albumen is executed in stable expression

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0811736B2 (en) * 1986-08-07 1996-02-07 財団法人化学及血清療法研究所 Cattle epidemic fever, Ibaraki disease, Akabane disease 3 types inactivated vaccine
GB9110808D0 (en) 1991-05-17 1991-07-10 Retroscreen Ltd Aids vaccine and method for its production
US6114108A (en) 1995-08-29 2000-09-05 V.I. Technologies, Inc. Methods and compositions for the selective modification of viral nucleic acids
CA2681159A1 (en) * 2007-03-13 2008-09-18 Peros Systems Technologies, Inc. Immunoactive compositions for improved oral delivery of vaccines and therapeutic agents
EP2062594A1 (en) 2007-11-21 2009-05-27 Wyeth Farma, S.A. Bluetongue virus vaccine and immunogenic compositions, methods of use and methods of producing same
DK2855513T3 (en) 2012-06-01 2017-03-13 Boehringer Ingelheim Vetmedica Gmbh SCHMALLENBERGVIRUS (SBV) VACCINE, PROCEDURES FOR MANUFACTURING AND USING THEREOF
WO2013178711A1 (en) 2012-06-01 2013-12-05 Boehringer Ingelheim Vetmedica Gmbh Genomic sequences of schmallenberg virus and uses thereof

Also Published As

Publication number Publication date
US9370562B2 (en) 2016-06-21
EP2855513B1 (en) 2016-12-07
AR091240A1 (en) 2015-01-21
CA2872961A1 (en) 2013-12-05
CN104350066B (en) 2018-06-19
IN2014DN08927A (en) 2015-05-22
AU2013267453A1 (en) 2014-11-13
DK2855513T3 (en) 2017-03-13
PL2855513T3 (en) 2017-05-31
MX363044B (en) 2019-03-06
AU2013267453B2 (en) 2017-04-06
CN104350066A (en) 2015-02-11
UY34840A (en) 2013-12-31
US20130323277A1 (en) 2013-12-05
US9872897B2 (en) 2018-01-23
US20160250317A1 (en) 2016-09-01
EA201401352A1 (en) 2015-05-29
EA034543B1 (en) 2020-02-19
JP2015519367A (en) 2015-07-09
EP2855513A1 (en) 2015-04-08
ES2617351T3 (en) 2017-06-16
JP6250649B2 (en) 2017-12-20
BR112014029515A2 (en) 2017-07-25
MX2014014521A (en) 2015-02-24
WO2013181270A1 (en) 2013-12-05
AU2013267453C1 (en) 2017-08-10

Similar Documents

Publication Publication Date Title
SG11201901700UA (en) Biaryl compounds useful as immunomodulators
SG11201805120YA (en) Zika virus vaccine
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201807912SA (en) Vaccine against rsv
SG11201808990QA (en) Compositions for topical application of compounds
SG11201804411TA (en) Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
SG11201804814YA (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
SG11201408318RA (en) Compositions and methods for transmucosal absorption
SG11201807809XA (en) A transient commensal microorganism for improving gut health
SG11201408307VA (en) Needle guard
SG11201407340YA (en) Treatment of myelosuppression
SG11201408459VA (en) Purification of virus like particles
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201810429UA (en) Anti-cd19 antibody formulations
SG11201808237UA (en) Substituted indole compound derivatives as dengue viral replication inhibitors
SG11201807051VA (en) Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy
SG11201807913XA (en) Stabilized soluble pre-fusion rsv f proteins
SG11201408292YA (en) Dry powder for inhalation formulation comprising salmeterol xinafoate, fluticasone propionate and tiotropium bromide, and method for preparing same
SG11201407597XA (en) Nucleophilic catalysts for oxime linkage
SG11201407619SA (en) Schmallenberg virus (sbv) vaccine, methods of production, and uses thereof
SG11201907207UA (en) Pharmaceutical combinations comprising an anti-ly75 antibody
SG11201810974QA (en) Methods and compositions for prostate cancer diagnosis and treatment
SG11201407599SA (en) Oligonucleotide chelate complex-polypeptide compositions and methods